JP5514268B2 - Pigmentation preventing or improving agent - Google Patents

Description

  The present invention relates to an agent for preventing or improving pigmentation, which can more effectively prevent or improve pigmentation on the skin.

  The deposition of pigments such as skin spots and freckles is a major cosmetic problem for women. Regarding the occurrence mechanism of skin spots and freckles, it is generally considered that melanin pigments are produced in the skin cells when the skin is stimulated by ultraviolet rays or the like and deposited. Therefore, as a means for preventing or improving the deposition of pigments such as stains and freckles, conventionally, arbutin, kojic acid, ascorbic acid, ascorbic acid derivatives, ellagic acid, lucinol, linoleic acid, tranexamic acid, chamomile extract, etc. Or the external preparation which mix | blended the component which suppresses the production | generation of melanin indirectly is used (for example, refer nonpatent literature 1). However, these external preparations have the problem that the effect of improving pigment deposition is slow and not sufficient. Ubiquinone is known to have an antioxidative effect, but the effect of preventing or improving pigment deposition is insufficient and not satisfactory.

  On the other hand, adenosine 5′-monophosphate (hereinafter referred to as AMP) is also known to have an action to improve skin pigmentation, and is used as an external preparation for the purpose of improving pigmentation. It has been found that it can be suitably used.

  However, there has been no example in which a specific melanin production inhibitor or ubiquinone and AMP are used in combination so far, and what effect is obtained by this is not known.

"Advances and future prospects of evaluation technology for cosmetics"; supervised by Katsuyuki Takeda, Shotaro Harada, Masanori Ando; Japanese Cosmetic Technology Society; Pharmaceutical Affairs Daily; pp. 149-159

  An object of this invention is to provide the pigmentation prevention or improvement agent which can exhibit the prevention or improvement effect of pigmentation more effectively.

  As a result of intensive studies to solve the above problems, the present inventors have found that (A) at least one selected from AMP and salts thereof, (B) arbutin, ellagic acid, 4-alkylresorcinol, tranexamic acid, It has been found that the effect of preventing or improving pigmentation is synergistically enhanced by combining at least one selected from a salt, chamomile extract and ubiquinone. The present invention has been developed through further studies based on such findings.

That is, the present invention is an agent for preventing or improving pigmentation listed below:
Item 1. (A) at least one selected from the group consisting of AMP and salts thereof, and (B) selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinol, tranexamic acid, salts thereof, chamomile extract, and ubiquinone An agent for preventing or improving pigmentation, comprising at least one selected from the group consisting of:
Item 2. Item 2. The pigmentation preventing or improving agent according to Item 1, which is a cosmetic, an external medicine, or a quasi-drug.

  The agent for preventing or improving pigmentation of the present invention contains both AMP and its salt as component (A) and a specific melanin inhibitor and ubiquinone as component (B) in combination. Has a synergistically enhanced effect of preventing or improving pigmentation. Therefore, the agent for preventing or improving pigmentation according to the present invention has a more excellent pigmentation preventing or improving effect, and is therefore a cosmetic for the purpose of whitening, prevention of skin aging, improvement of dullness and improvement of melasma. It is also useful as a skin external preparation (pharmaceutical, quasi-drug).

  In addition, the components (A) and (B) which are active ingredients of the pigmentation prevention or ameliorating agent of the present invention are both confirmed to be highly safe and have the advantage that they can be used on a daily basis as cosmetics. is there. Therefore, according to the pigmentation prevention or amelioration agent of the present invention, pigmentation can be prevented or improved by a simple method of using cosmetics and less burden on the user.

FIG. 1 shows a visual comparison score (improvement effect of pigmentation) in Example 1 (combination of AMP2Na and arbutin), Comparative Example 1-1 (AMP2Na) and Comparative Example 1-2 (Arbutin). FIG. FIG. 2 shows the results of Test Example 2 in Example 2 (combination of AMP2Na and ellagic acid hydrate), Comparative Test Example 2-1 (AMP2Na), and Comparative Test Example 2-2 (Elagic acid hydrate). It is a figure which shows a visual comparative score (index of the pigmentation improvement effect). FIG. 3 shows a visual comparison score (pigmentation) in Test Example 3 according to Test Example 3 (combination of AMP2Na and tranexamic acid), Comparative Test Example 3-1 (AMP2Na) and Comparative Test Example 3-2 (tranexamic acid). It is a figure which shows the parameter | index of an improvement effect. FIG. 4 shows an experimental test example 4 (combination of AMP2Na and 4-n-hexylresorcinol), comparative test example 4-1 (AMP2Na) and comparative test example 4-2 (4-n-hexylresorcinol) in Test Example 4. It is a figure which shows (triangle | delta) visual comparison score (index of the pigmentation improvement effect) by. FIG. 5 is a visual comparison score (pigmentation) in Test Example 5 according to Test Example 5 (combination of AMP2Na and chamomile extract), Comparative Test Example 5-1 (AMP2Na), and Comparative Test Example 5-2 (camomile extract). It is a figure which shows the parameter | index of an improvement effect. FIG. 6 is a visual comparison score (pigmentation) in Test Example 6 according to Test Example 6 (combination of AMP2Na and coenzyme Q10), Comparative Test Example 6-1 (AMP2Na) and Comparative Test Example 6-2 (Coenzyme Q10). It is a figure which shows the parameter | index of an improvement effect.

  The present invention is described in detail below.

  The agent for preventing or improving pigmentation of the present invention contains at least one selected from the group consisting of AMP and salts thereof (hereinafter referred to as “component (A)”).

  In the present invention, the salt of AMP used as the component (A) is not particularly limited as long as it can be blended in cosmetics, external medicines or quasi drugs. Specific examples of AMP salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts, magnesium salts and barium salts; basic amino acid salts such as arginine and lysine; Examples include ammonium salts such as tricyclohexylammonium salt; various alkanolamine salts such as monoethanolamine salt, diethanolamine salt, triethanolamine salt, monoisopropanolamine salt, diisopropanolamine salt, and triisopropanolamine. Alkali metal salts such as sodium salts are preferred. Specific examples of such alkali metal salts include adenosine monophosphate monosodium and adenosine monophosphate disodium. These AMP salts may be used alone or in any combination of two or more.

  The ratio of the component (A) to be blended in the pigmentation preventing or improving agent of the present invention is not particularly limited, and is appropriately set according to the form of the agent, the type of the component (A), the expected effect, and the like. be able to. As an example, the total amount of the component (A) is 0.05 to 10% by weight, preferably 0.1 to 7% by weight, more preferably 0.5 to 6% by weight based on the total weight of the pigmentation preventing or improving agent. % Can be mentioned.

  In addition to the above component (A), the pigmentation preventing or improving agent of the present invention includes arbutin (chemical names 4-hydroxyphenyl-β-D glucopyranoside and 4-hydroxyphenyl-α-D glucopyranoside), ellagic acid, 4- It contains at least one selected from the group consisting of alkylresorcinol, tranexamic acid, salts thereof, chamomile extract, and ubiquinone (hereinafter referred to as “component (B)”).

  The arbutin may be α type or β type.

  Specific examples of the 4-alkylresorcinol include 4-methylresorcinol, 4-ethylresorcinol, 4-n-propylresorcinol, 4-n-butylresorcinol, 4-n-pentylresorcinol, 4-n-hexylresorcinol. Etc. are exemplified. Among these, 4-n-butylresorcinol, 4-n-pentylresorcinol and 4-n-hexylresorcinol are preferable, and 4-n-butylresorcinol and 4-n-hexylresorcinol are more preferable.

  Among the components (B), arbutin, ellagic acid, 4-alkylresorcinol, and tranexamic acid may be in the form of a salt as long as they are cosmetically or pharmaceutically acceptable. Examples of these salts include the same alkali metal salts, alkaline earth metal salts, basic amino acid salts, ammonium salts and alkanolamine salts as the AMP salts.

Chamomile extract is an extract obtained by extracting flowers and / or stems of chamomile (Matricaria chamomilla) with a solvent. The chamomile extract is dried, shredded, crushed, pressed or boiled with chamomile flowers and / or stems as necessary, and is water, an organic solvent, or a mixture of water and an organic solvent at room temperature. Or it can acquire by extracting under heating. Examples of the organic solvent used in this extraction include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propanol, isopropanol, and butanol, propylene glycol, 1,3-butylene glycol, acetone, ethyl acetate, chloroform, and toluene. , Pentane, hexane, heptane and the like alone or in combination of two or more. The extraction solvent is preferably water, a lower alcohol having 1 to 5 carbon atoms, and a mixed solution of the alcohol and water, particularly preferably ethanol or a mixed solution of ethanol and water. When using a mixed liquid of a lower alcohol having 1 to 5 carbon atoms and water, the content of the alcohol with respect to the total weight of the mixed liquid is, for example, 0.01 to 100% by weight, preferably 5 to 55% by weight, More preferably, the ratio which becomes 45 to 55 weight% can be mentioned. Chamomile extract is commercially available, and a commercially available product can be used conveniently.

  In the present invention, the chamomile extract may be used in any form such as an extract, an extract concentrate, a purified product, a dried product, a solution of a dried product, and a fraction.

  The ubiquinone is not particularly limited, and examples thereof include coenzyme Q6, coenzyme Q7, coenzyme Q8, coenzyme Q9, and coenzyme Q10. Among these, Preferably, coenzyme Q10 is mentioned.

  The ratio of the component (B) to be blended in the pigmentation preventing or improving agent of the present invention is not particularly limited, and can be appropriately set according to the form of the agent, expected effects, and the like. As an example, as the blending ratio of the component (B), a range in which the total amount of the component (B) is 0.00001 to 100 parts by weight with respect to 1 part by weight of the blended component (A) is given. Can do. More specifically, when component (B) is arbutin, ellagic acid, 4-alkylresorcinol, tranexamic acid, and / or a salt thereof, the total weight of component (A) is 1 part by weight. The component (B) is a total amount, preferably 0.1 to 100 parts by weight, more preferably 1 to 100 parts by weight. Further, for example, when the component (B) is a chamomile extract, the component (B) is a total amount, preferably 0.00001 to 10 parts by weight, with respect to 1 part by weight of the component (A). A range of 0.0001 to 10 parts by weight is preferable. In addition, for example, when the component (B) is ubiquinone, the component (B) is a total amount, preferably 0.001 to 100 parts by weight, more preferably 1 part by weight of the total weight of the component (A). May be in the range of 0.01 to 100 parts by weight. In addition, in the mixture ratio of the said (B) component, chamomile extract shows the value converted into solid content. By using a combination of the component (A) and the component (B) at such a ratio, the pigmentation prevention or improvement action of both these components is synergistically enhanced, and a further excellent pigmentation inhibitory effect is achieved. The

  Moreover, as a ratio of (B) component with respect to the total amount of a pigmentation prevention or improvement agent, (B) component can mention 0.0001-50 weight% in total amount, for example. More specifically, when component (B) is arbutin, ellagic acid, 4-alkylresorcinol, tranexamic acid, and / or a salt thereof, component (B) is 0.01 to 50% by weight in total. , Preferably 0.05 to 30% by weight, more preferably 0.1 to 20% by weight. For example, when the component (B) is a chamomile extract, the total amount of the component (B) is 0.0001 to 0.5% by weight, preferably 0.0005 to 0.3% by weight, more preferably 0. 0.001 to 0.2% by weight. For example, when the component (B) is ubiquinone, the total amount of the component (B) is 0.0001 to 50% by weight, preferably 0.001 to 30% by weight, more preferably 0.01 to 20% by weight. %. In addition, in the mixture ratio of the said (B) component, chamomile extract shows the value converted into solid content.

The agent for preventing or improving pigmentation of the present invention is used in a form for transdermal application such as cosmetics, external medicines or quasi drugs. The form of the agent for preventing and treating pigmentation is not particularly limited as long as it is applicable to the skin and mucous membranes. For example, an aqueous solution system, a solubilization system, an emulsification system, a powder dispersion system, and a water / oil two-layer system Arbitrary forms are mentioned. Specifically, liquid agents, oil agents, lotions, liniments, emulsions, suspensions, creams, ointments and the like can be exemplified. In particular, in the case of a cosmetic, examples include lotions; emulsions such as emollient emulsions, milky lotions, nourishing emulsions, and cleansing emulsions; creams such as emollient creams, massage creams, cleansing creams, and makeup creams. Further, the pigmentation preventing or improving agent of the present invention may be in the form of a hair care product such as a hair restorer, and specific examples of such a hair care product include tonics, hair creams, hair lotions, aerosols (spraying agents), Examples include mousse, shampoo, rinse, liquid and the like.

  The pigmentation preventive or ameliorating agent of the present invention can be blended with various known ingredients that are blended in compositions that are applied to the skin and mucous membranes of cosmetics, external pharmaceuticals and quasi drugs. Examples of such components include surfactants, pigments (dyes, pigments), fragrances, preservatives, bactericides (antibacterial agents), thickeners, antioxidants, metal sequestering agents, cooling agents, deodorants, etc. In addition to various additives, moisturizers, UV absorbers, UV scattering agents, vitamins, plant extracts, skin astringents, anti-inflammatory agents (anti-inflammatory agents), whitening agents, cell activators, vasodilators, blood circulation promoters And skin function enhancers. In addition, a base or carrier known per se can be used according to the various forms described above.

  Among the above components, examples of the surfactant include higher fatty acid soap, alkyl sulfate ester salt, polyoxyethylene alkyl ether sulfate salt, alkyl ether phosphate ester salt, N-acyl amino acid salt, and acyl N-methyl taurate salt. Anionic surfactants; cationic surfactants such as alkyltrimethylammonium chloride and dialkyldimethylammonium chloride; alkyldimethylaminoacetic acid betaines, alkylamidodimethylaminoacetic acid betaines, 2-alkyl-N-carboxy-N-hydroxyimidazolinium betaines, etc. Amphoteric surfactants such as: polyoxyethylene type, polyhydric alcohol ester type, and nonionic surfactants such as ethylene oxide / propylene oxide block copolymers. Moreover, it does not restrict | limit in particular, The surfactant which belongs to a polymeric surfactant or a natural surfactant can also be used.

  Examples of preservatives include ethyl paraoxybenzoate, salicylic acid, and sorbic acid. Examples of the thickener include xanthan gum, sodium carboxymethylcellulose, carboxyvinyl polymer and the like. Examples of the metal sequestering agent include sodium salt of ethylenediaminetetraacetic acid, phosphoric acid, citric acid and the like.

  The agent for preventing or improving pigmentation is used by directly applying or spraying on the skin depending on the form. The amount of the pigmentation prevention or ameliorating agent used and the number of times of use per day are appropriately set according to the age, sex, application, degree of symptoms, etc. of the user. For example, an appropriate amount of the agent is used once. May be applied percutaneously to the skin at a frequency of 5 or 6 times / day.

  Since the pigmentation preventing or improving agent can prevent or improve pigmentation on the skin, it is also useful as a whitening agent, skin anti-aging agent, dullness improving agent, or melasma improving agent.

EXAMPLES Hereinafter, although an Example and a test example are given and this invention is demonstrated, this invention is not limited to these Examples. In the following Examples and Test Examples, the chamomile extract uses “Kamitsu Liquid” (liquid, solid content 0.9% by weight, manufactured by Ichimaru Falcos), and the amount of chamomile extract blended with “Kamitsu Liquid” itself. Indicates the amount.

Example 1 Lotion (wt%)
AMP 2.0
Arbutin 3.0
1,3-butylene glycol 2.0
Concentrated glycerin 2.0
Polyoxyethylene methyl polysiloxane copolymer 0.3
Ethanol 5.0
Preservative appropriate amount pH adjuster Adjust to pH 6.5
Purified water residue
Total 100.0

Example 2 Lotion (wt%)
AMP 2.0
Tranexamic acid 3.0
Dipropylene glycol 3.0
Concentrated glycerin 2.0
Polyoxyethylene sorbitan monolaurate (20E.O.) 1.0
Ethanol 10.0
Preservative appropriate amount pH adjuster Adjust to pH 6.5 Perfume proper amount
Purified water residue
Total 100.0

Example 3 Cream (% by weight)
AMP 2.0
Ellagic acid 0.5
Polyoxyalkylene alkyl co-modified silicon 2.0
Decamethylcyclopentasiloxane 18.0
Liquid paraffin 4.0
Concentrated glycerin 3.0
1,3-butylene glycol 3.0
Ethanol 5.0
Preservative appropriate amount pH adjuster Adjust to pH 6.5
Purified water residue
Total 100.0

Example 4 serum (% by weight)
AMP2Na 1.5
Chamomile extract (trade name “Kamitsu Liquid”, manufactured by Ichimaru Falcos) 5.0
Dipropylene glycol 3.0
Concentrated glycerin 3.0
Sodium hyaluronate 0.2
Xanthan gum 0.2
Polyoxyethylene methyl polysiloxane copolymer 0.3
Ethanol 3.0
Preservative appropriate amount pH adjuster Adjust to pH 6.5 Perfume proper amount
Purified water residue
Total 100.0

Example 5 Latex (wt%)
AMP2Na 1.0
4-hexylresorcinol 0.5
Ascorbyl tetra-2-hexyldecanoate 2.0
Polyoxyalkylene alkyl co-modified silicon 1.0
Decaglyceryl monostearate2.0
Glyceryl monostearate1.0
Stearic acid 3.0
Behenyl alcohol 2.0
Glyceryl tri-2-ethylhexanoate 5.0
Squalane 2.0
Decamethylcyclopentasiloxane 1.0
Hydrogenated soybean phospholipid 0.3
Dl-α-Tocopherol acetate 0.1
Concentrated glycerin 3.0
1,3-butylene glycol 3.0
Carboxyvinyl polymer 0.3
Preservative appropriate amount pH adjuster Adjust to pH 6.5
Purified water residue
Total 100.0

Test Example 1 Evaluation of Pigmentation Improvement Effect-1
In order to confirm the pigmentation improving effect obtained by using AMP and arbutin in combination, the following test was conducted using colored guinea pigs.
<Reagent preparation and model animal production>
1. Preparation of coated specimen Based on 20% by weight ethanol aqueous solution as a base, a mixed solution of 3% by weight AMP2Na and 3% by weight arbutin (β type) (Example Test 1), a solution containing 3% by weight AMP2Na (Comparative Test Example 1-1) ) And a 3 wt% arbutin (β-type) -containing solution (Comparative Test Example 1-2).

2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experiment method>
From 11 days after the end of ultraviolet irradiation, the coated specimen was applied twice a day for 14 consecutive days. An appropriate amount of each of three types of coated specimens (Execution Test Example 1, Comparative Test Examples 1-1 and 1-2) and a 20% by weight ethanol aqueous solution (control) was applied to each animal. Five assessors compared the brightness of the skin where each applied specimen and control were applied 14 days later according to Scheffe's paired comparison method, and scored according to the criteria shown in Table 1.

<Calculation method>
Before the start of application and 14 days after the start, five judges for each colored guinea pig scored the control and each coated specimen as a comparative score, and the visual comparative scores of the respective judges were totaled to obtain a visual comparative score for each coated specimen. . The average value of visual comparison scores of 8 colored guinea pigs was calculated for each coated specimen. The Δ visual comparison score was calculated by subtracting the visual comparison score before coating from the visual comparison score 14 days after the start of coating. In addition, it means that the larger the calculated visual comparison score, the brighter the color compared to the base material, and the larger the Δ visual comparison score, the greater the effect of improving pigmentation.

<Results and discussion>
The obtained results are shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 14 days after coating was 1.00 in Comparative Test Example 1-1 and 0.50 in Comparative Test Example 1-2, whereas the test was conducted. In Example 1, it was 5.50. That is, the sum of the Δ visual comparison scores of Comparative Test Examples 1 and 2 is 1.50, and the Δ visual comparison score of Example Test Example 1 is 5.50. Therefore, in Example Test Example 1, AMP2Na and arbutin were used in combination. It was revealed that the pigmentation improving effect was synergistically enhanced.

Test Example 2 Evaluation of pigmentation improving effect-2
<Reagent preparation and model animal production>
1. Preparation of coated specimen Based on 20% by weight ethanol aqueous solution as a base, a mixed solution of 3% by weight AMP2Na and 0.5% by weight ellagic acid hydrate (Example 2), a solution containing 3% by weight AMP2Na (Comparative Test Example 2) -1) and a 0.5 wt% ellagic acid hydrate-containing solution (Comparative Test Example 2-2).

2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experiment method>
The test was performed in the same manner as in Test Example 1 except that eight colored guinea pigs were used and the coating specimen coating period was 28 days.

<Calculation method>
A Δ visual comparison score was calculated in the same manner as in Test Example 1.

<Results and discussion>
The obtained results are shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 28 days after application was 1.25 in Comparative Test Example 2-1 and 3.25 in Comparative Test Example 2-2, while it was an implementation test. In Example 2, it was 10.50. That is, since the sum of the Δ visual comparison scores of Comparative Test Examples 2-1 and 2-2 is 4.50, and the Δ visual comparison score of Test Example 2 is 10.50, in Test Example 2, AMP2Na and ellagic acid are used. It was confirmed that the pigmentation improving effect was synergistically enhanced by using the hydrate together.

Test Example 3 Evaluation of Pigmentation Improvement Effect-3
In order to confirm the pigmentation improving effect obtained by using AMP and tranexamic acid in combination, the following test was performed using colored guinea pigs.
<Reagent preparation and model animal production>
1. Preparation of coated specimen Based on a 20 wt% aqueous ethanol solution, a mixed solution of 3 wt% AMP2Na and 3 wt% tranexamic acid (Example 3), 3 wt% AMP2Na-containing solution (Comparative Test Example 3-1)
And a 3 wt% tranexamic acid-containing solution (Comparative Test Example 3-2).

2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experiment method>
The test was conducted in the same manner as in Test Example 1 using 8 colored guinea pigs.

<Calculation method>
A Δ visual comparison score was calculated in the same manner as in Test Example 1.

<Results and discussion>
The obtained results are shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 14 days after application was 1.75 in Comparative Test Example 3-1, and 1.25 in Comparative Test Example 3-2, while the test was conducted. In Example 3, it was 4.50. That is, the sum of the Δ visual comparison score of Comparative Test Examples 3-1 and 3-2 is 3.00, and the Δ visual comparison score of Test Example 3 is 4.50. Therefore, in Test Example 3, AMP2Na and tranexamic acid are used. It was confirmed that the pigmentation improving effect was synergistically enhanced by using together.

Test Example 4 Evaluation of Pigmentation Improvement Effect-4
<Reagent preparation and model animal production>
1. Preparation of coated specimen Based on 20% by weight aqueous ethanol solution, mixed solution of 3% by weight AMP2Na and 0.3% by weight 4-n-hexylresorcinol (Example 4), 3% by weight AMP2Na-containing solution (Comparative Test Example) 4-1) and a 0.3 wt% 4-n-hexylresorcinol-containing solution (Comparative Test Example 4-2) were prepared.
2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experimental method and calculation method>
An experiment was performed in the same manner as in Test Example 1 above, and a Δ visual comparison score was calculated.

<Results and discussion>
The obtained results are shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 14 days after the application was 1.25 in Comparative Test Example 4-1, and 1.75 in Comparative Test Example 4-2, while it was an implementation test. In Example 4, it was 7.25. That is, since the sum of the Δ visual comparison scores of Comparative Test Examples 4-1 and 4-2 is 3.00 and the Δ visual comparison score of Example 4 is 7.25, AMP2Na and 4-n-hexylresorcinol are used in combination. By doing so, it was confirmed that the pigmentation improving effect was synergistically enhanced.

Test Example 5 Evaluation of Pigmentation Improvement Effect-5
<Reagent preparation and model animal production>
1. Preparation of coated specimen Based on 20% by weight ethanol aqueous solution, mixed solution of 3% by weight AMP2Na and 5% by weight chamomile extract (trade name “Kamitsu Liquid”, manufactured by Ichimaru Falcos) (Example 5) 3% by weight An AMP2Na-containing solution (Comparative Test Example 5-1) and a 5 wt% chamomile extract-containing solution (Comparative Test Example 5-2) were prepared.

2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experimental method and calculation method>
An experiment was conducted in the same manner as in Test Example 1 above, and a Δ visual comparison score was calculated.

<Results and discussion>
The obtained results are shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 14 days after the coating was 1.13 in Comparative Test Example 5-1, and 0.50 in Comparative Test Example 5-2, while it was an implementation test. In Example 5, it was 3.00. That is, the sum of the Δ visual comparison scores of Comparative Test Examples 5-1 and 5-2 is 1.63, and the Δ visual comparison score of Example 5 is 3.00. Therefore, by using AMP2Na and chamomile extract together, It was confirmed that the pigmentation improving effect was synergistically enhanced.

Test Example 6 Evaluation of Pigmentation Improvement Effect-6
<Reagent preparation and model animal production>
1. Preparation of a coated specimen Based on a 20 wt% aqueous ethanol solution, a mixed solution of 3 wt% AMP2Na and 1 wt% coenzyme Q10 (Example 6), a 3 wt% AMP2Na-containing solution (Comparative Test Example 6-1), and A 1 wt% coenzyme Q10-containing solution (Comparative Test Example 6-2) was prepared.

2. Preparation of pigmentation model animals The backs of 8 colored guinea pigs were shaved and then irradiated with ultraviolet rays several times to prepare 4 pigmentation sites per animal.

<Experimental method and calculation method>
An experiment was conducted in the same manner as in Test Example 1 above, and a Δ visual comparison score was calculated.

<Results and discussion>
The obtained result is shown in FIG. The visual comparison score obtained by subtracting the visual comparison score before the start of coating from the visual comparison score 14 days after the coating was 1.25 in Comparative Test Example 6-1 and 0.63 in Comparative Test Example 6-2, while it was an implementation test. In Example 6, it was 3.88. That is, since the sum of the Δ visual comparison scores of Comparative Test Examples 6-1 and 6-2 is 1.88, and the Δ visual comparison score of Example 6 is 3.88, by using AMP2Na and coenzyme Q10 together, It was confirmed that the pigmentation improving effect was synergistically enhanced.

Claims (3)

Use of the following (A) component and (B) component for manufacturing the cosmetics for prevention or improvement of pigmentation , an external pharmaceutical, or a quasi-drug ;
(A) an alkali metal salt of adenosine 5′-monophosphate, and (B) at least one selected from the group consisting of arbutin and its salt. Use of Claim 1 whose said (B) component is 0.00001-100 weight part with respect to 1 weight part of said (A) component in cosmetics, an external pharmaceutical, or a quasi-drug . In cosmetics, an external medicine, or a quasi-drug, the said (A) component is 0.05 to 10 weight%, The said (B) component is 0.0001 to 50 weight% contained, It is to 1 or 2 Use of description.

Images